Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Transplantation | 21 | 2008 | 1305 | 1.460 |
Why?
|
Lung Diseases, Obstructive | 7 | 2000 | 309 | 0.470 |
Why?
|
Bronchiolitis Obliterans | 5 | 2006 | 213 | 0.400 |
Why?
|
Cystic Fibrosis | 4 | 2003 | 1274 | 0.320 |
Why?
|
Oseltamivir | 1 | 2008 | 76 | 0.300 |
Why?
|
Waiting Lists | 2 | 2002 | 763 | 0.290 |
Why?
|
Lung | 11 | 2016 | 9994 | 0.280 |
Why?
|
Oxygen Consumption | 7 | 2002 | 1843 | 0.280 |
Why?
|
Asbestos | 4 | 1992 | 251 | 0.270 |
Why?
|
Respiratory Mechanics | 4 | 1998 | 699 | 0.230 |
Why?
|
Living Donors | 2 | 2006 | 636 | 0.230 |
Why?
|
Hemangioma, Capillary | 1 | 2003 | 62 | 0.220 |
Why?
|
Smad4 Protein | 1 | 2024 | 191 | 0.210 |
Why?
|
Lung Diseases | 6 | 2005 | 1915 | 0.210 |
Why?
|
Anaerobic Threshold | 1 | 2002 | 52 | 0.200 |
Why?
|
Cardiac Output | 3 | 2001 | 838 | 0.200 |
Why?
|
Muromonab-CD3 | 2 | 1999 | 104 | 0.200 |
Why?
|
Doxycycline | 1 | 2003 | 341 | 0.190 |
Why?
|
Oxygen Inhalation Therapy | 2 | 2001 | 404 | 0.190 |
Why?
|
Graft Rejection | 6 | 2008 | 4426 | 0.180 |
Why?
|
Vascular Resistance | 3 | 2002 | 933 | 0.170 |
Why?
|
Pulmonary Ventilation | 2 | 1998 | 371 | 0.170 |
Why?
|
Forced Expiratory Volume | 9 | 2006 | 1809 | 0.170 |
Why?
|
Pulmonary Medicine | 1 | 2020 | 221 | 0.150 |
Why?
|
T-Lymphocytes | 10 | 2005 | 10181 | 0.150 |
Why?
|
Perfusion | 1 | 2002 | 1376 | 0.140 |
Why?
|
Antiviral Agents | 2 | 2008 | 3061 | 0.140 |
Why?
|
Hypertension, Pulmonary | 4 | 2002 | 1570 | 0.140 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 1992 | 748 | 0.140 |
Why?
|
Lactic Acid | 1 | 2002 | 1134 | 0.140 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2000 | 364 | 0.140 |
Why?
|
Lidocaine | 2 | 1990 | 538 | 0.140 |
Why?
|
Influenza, Human | 1 | 2008 | 1528 | 0.140 |
Why?
|
Advisory Committees | 1 | 2020 | 788 | 0.130 |
Why?
|
Serum Amyloid P-Component | 1 | 2016 | 46 | 0.130 |
Why?
|
Exercise Test | 8 | 2016 | 2128 | 0.130 |
Why?
|
Killer Cells, Natural | 3 | 1990 | 2203 | 0.120 |
Why?
|
Exercise Tolerance | 2 | 1998 | 830 | 0.120 |
Why?
|
Smoking | 10 | 2000 | 9073 | 0.110 |
Why?
|
International Cooperation | 1 | 2020 | 1433 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 1 | 2003 | 2049 | 0.110 |
Why?
|
Health Status | 1 | 2006 | 4081 | 0.110 |
Why?
|
Respiratory Tract Diseases | 1 | 1999 | 748 | 0.110 |
Why?
|
Respiratory Function Tests | 8 | 2016 | 1683 | 0.110 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2014 | 245 | 0.100 |
Why?
|
Postoperative Complications | 4 | 2008 | 15697 | 0.100 |
Why?
|
Pulmonary Emphysema | 2 | 2014 | 688 | 0.100 |
Why?
|
Mental Health | 1 | 2006 | 3213 | 0.100 |
Why?
|
Vital Capacity | 3 | 2006 | 965 | 0.100 |
Why?
|
Opportunistic Infections | 2 | 2008 | 377 | 0.100 |
Why?
|
Alveolitis, Extrinsic Allergic | 1 | 1992 | 62 | 0.100 |
Why?
|
Immunosuppressive Agents | 3 | 1999 | 4166 | 0.090 |
Why?
|
Asbestosis | 1 | 1991 | 81 | 0.090 |
Why?
|
Occupational Exposure | 2 | 1992 | 1809 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3113 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2014 | 662 | 0.090 |
Why?
|
alpha 1-Antitrypsin Deficiency | 3 | 2008 | 113 | 0.090 |
Why?
|
Hemodynamics | 5 | 2001 | 4174 | 0.090 |
Why?
|
Lung Neoplasms | 6 | 2003 | 13262 | 0.090 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2016 | 502 | 0.090 |
Why?
|
Survival Analysis | 5 | 2004 | 10182 | 0.090 |
Why?
|
Adult | 39 | 2024 | 219994 | 0.090 |
Why?
|
Vasodilation | 3 | 2002 | 962 | 0.080 |
Why?
|
Tandem Repeat Sequences | 3 | 2005 | 180 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 5 | 2005 | 3224 | 0.080 |
Why?
|
Receptors, Interleukin-2 | 1 | 1990 | 562 | 0.080 |
Why?
|
Pulmonary Gas Exchange | 3 | 1998 | 378 | 0.080 |
Why?
|
Societies, Medical | 1 | 2020 | 3905 | 0.080 |
Why?
|
Male | 48 | 2024 | 359744 | 0.080 |
Why?
|
Walking | 1 | 1995 | 1189 | 0.080 |
Why?
|
Dermatomycoses | 1 | 2008 | 48 | 0.070 |
Why?
|
Aspergillus | 1 | 2008 | 92 | 0.070 |
Why?
|
Phenotype | 3 | 2024 | 16546 | 0.070 |
Why?
|
Organ Transplantation | 1 | 1998 | 1150 | 0.070 |
Why?
|
Dyspnea | 2 | 2014 | 1352 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 4 | 1990 | 4024 | 0.070 |
Why?
|
Humans | 60 | 2024 | 760621 | 0.070 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2006 | 94 | 0.070 |
Why?
|
Homeodomain Proteins | 1 | 2016 | 2414 | 0.070 |
Why?
|
Total Lung Capacity | 1 | 2006 | 149 | 0.070 |
Why?
|
Middle Aged | 34 | 2016 | 220352 | 0.070 |
Why?
|
Aspergillosis | 1 | 2008 | 243 | 0.060 |
Why?
|
Flow Cytometry | 5 | 1992 | 5870 | 0.060 |
Why?
|
Trachea | 3 | 2006 | 1082 | 0.060 |
Why?
|
Receptors, Leukotriene B4 | 1 | 2005 | 92 | 0.060 |
Why?
|
Female | 41 | 2024 | 391270 | 0.060 |
Why?
|
Hemolysis | 1 | 1987 | 423 | 0.060 |
Why?
|
Bronchial Diseases | 1 | 2005 | 151 | 0.060 |
Why?
|
Chemokines, CXC | 1 | 2006 | 421 | 0.060 |
Why?
|
Maximal Midexpiratory Flow Rate | 1 | 2004 | 76 | 0.060 |
Why?
|
Stroke Volume | 5 | 2003 | 5523 | 0.060 |
Why?
|
Physical Endurance | 1 | 2006 | 363 | 0.060 |
Why?
|
Chromosomes, Human, Pair 12 | 2 | 2002 | 430 | 0.060 |
Why?
|
Tissue Donors | 2 | 2004 | 2313 | 0.060 |
Why?
|
Facies | 1 | 2024 | 223 | 0.050 |
Why?
|
Clubfoot | 1 | 2024 | 87 | 0.050 |
Why?
|
Cryptorchidism | 1 | 2024 | 151 | 0.050 |
Why?
|
Tissue and Organ Harvesting | 1 | 2006 | 377 | 0.050 |
Why?
|
Hand Deformities, Congenital | 1 | 2024 | 174 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2006 | 655 | 0.050 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2005 | 663 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
Nitric Oxide | 2 | 2002 | 2141 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Transplantation Chimera | 1 | 2005 | 595 | 0.050 |
Why?
|
Pulmonary Fibrosis | 2 | 2006 | 506 | 0.050 |
Why?
|
Spirometry | 4 | 2002 | 924 | 0.050 |
Why?
|
Residual Volume | 1 | 2002 | 41 | 0.050 |
Why?
|
Oxygen | 4 | 2002 | 4193 | 0.050 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2003 | 590 | 0.050 |
Why?
|
Endothelium | 1 | 2003 | 764 | 0.050 |
Why?
|
Sarcoidosis | 2 | 1986 | 520 | 0.050 |
Why?
|
Boston | 3 | 2002 | 9280 | 0.050 |
Why?
|
Pulmonary Artery | 2 | 2001 | 1921 | 0.050 |
Why?
|
Nitroprusside | 1 | 2001 | 273 | 0.050 |
Why?
|
Adenocarcinoma | 3 | 1990 | 6315 | 0.040 |
Why?
|
Nifedipine | 1 | 2001 | 221 | 0.040 |
Why?
|
Tracheal Diseases | 1 | 2001 | 115 | 0.040 |
Why?
|
Ventricular Function, Right | 2 | 2003 | 610 | 0.040 |
Why?
|
Treatment Outcome | 7 | 2016 | 65017 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2002 | 442 | 0.040 |
Why?
|
Hospitals, General | 1 | 2024 | 795 | 0.040 |
Why?
|
Ribavirin | 2 | 2000 | 396 | 0.040 |
Why?
|
Antibodies, Monoclonal | 7 | 1987 | 9185 | 0.040 |
Why?
|
Radionuclide Ventriculography | 1 | 1998 | 40 | 0.040 |
Why?
|
Growth Disorders | 1 | 2024 | 653 | 0.040 |
Why?
|
Complement C3b | 1 | 1999 | 99 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2006 | 2659 | 0.040 |
Why?
|
Bronchoconstriction | 1 | 1999 | 139 | 0.040 |
Why?
|
Patient Selection | 2 | 2001 | 4283 | 0.040 |
Why?
|
Complement Membrane Attack Complex | 1 | 1999 | 105 | 0.040 |
Why?
|
Respiratory System Agents | 1 | 1998 | 30 | 0.040 |
Why?
|
Aerobiosis | 1 | 1998 | 101 | 0.040 |
Why?
|
Complement C4b | 1 | 1999 | 132 | 0.040 |
Why?
|
Helium | 1 | 1998 | 119 | 0.040 |
Why?
|
Complement C4 | 1 | 1999 | 244 | 0.040 |
Why?
|
Blood Gas Analysis | 2 | 1998 | 379 | 0.040 |
Why?
|
Vasodilator Agents | 1 | 2002 | 978 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 4 | 1990 | 1351 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2002 | 12159 | 0.040 |
Why?
|
Administration, Inhalation | 4 | 2002 | 1156 | 0.040 |
Why?
|
Quality of Life | 3 | 2006 | 13308 | 0.040 |
Why?
|
Acute Disease | 3 | 2004 | 7269 | 0.040 |
Why?
|
Physical Fitness | 1 | 2001 | 732 | 0.040 |
Why?
|
Survival Rate | 2 | 2004 | 12808 | 0.040 |
Why?
|
Chromosome Mapping | 2 | 2002 | 4625 | 0.030 |
Why?
|
Genetic Linkage | 1 | 2002 | 2381 | 0.030 |
Why?
|
Retrospective Studies | 9 | 2008 | 80372 | 0.030 |
Why?
|
Pneumonia | 1 | 2008 | 2131 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 5 | 2001 | 20509 | 0.030 |
Why?
|
Physical Exertion | 1 | 1998 | 662 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2002 | 15289 | 0.030 |
Why?
|
Myocardial Contraction | 1 | 2001 | 1516 | 0.030 |
Why?
|
Adolescent | 7 | 2024 | 87810 | 0.030 |
Why?
|
Maximal Expiratory Flow-Volume Curves | 1 | 1994 | 25 | 0.030 |
Why?
|
Aged | 15 | 2016 | 169152 | 0.030 |
Why?
|
Length of Stay | 3 | 1999 | 6479 | 0.030 |
Why?
|
Radiography | 2 | 2014 | 6965 | 0.030 |
Why?
|
Linear Models | 2 | 1995 | 5877 | 0.030 |
Why?
|
Klippel-Trenaunay-Weber Syndrome | 1 | 1995 | 69 | 0.030 |
Why?
|
Leukocyte Count | 3 | 1983 | 1600 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2006 | 3448 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1999 | 749 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3441 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 1999 | 643 | 0.030 |
Why?
|
Bronchoscopy | 2 | 2001 | 911 | 0.030 |
Why?
|
Infection Control | 1 | 2001 | 983 | 0.030 |
Why?
|
Immunoglobulin E | 1 | 1999 | 1484 | 0.030 |
Why?
|
Kidney Transplantation | 2 | 1999 | 4215 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 2 | 1992 | 1810 | 0.030 |
Why?
|
Therapeutic Irrigation | 2 | 1986 | 292 | 0.030 |
Why?
|
Genotype | 2 | 2024 | 12960 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2001 | 944 | 0.030 |
Why?
|
Follow-Up Studies | 5 | 2004 | 39261 | 0.030 |
Why?
|
Genome, Human | 2 | 2002 | 4417 | 0.020 |
Why?
|
Respiration | 1 | 1998 | 1654 | 0.020 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2003 | 2128 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 1990 | 6131 | 0.020 |
Why?
|
Piperazines | 1 | 2002 | 2525 | 0.020 |
Why?
|
Herpes Zoster | 1 | 2014 | 251 | 0.020 |
Why?
|
Age of Onset | 3 | 2004 | 3301 | 0.020 |
Why?
|
Time Factors | 5 | 2002 | 40165 | 0.020 |
Why?
|
Forecasting | 1 | 2001 | 2932 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2005 | 4550 | 0.020 |
Why?
|
Lod Score | 2 | 2002 | 602 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8803 | 0.020 |
Why?
|
Netherlands | 1 | 2016 | 2213 | 0.020 |
Why?
|
Risk Factors | 5 | 2002 | 74359 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10827 | 0.020 |
Why?
|
Pedigree | 3 | 2004 | 4578 | 0.020 |
Why?
|
Sex Factors | 1 | 2004 | 10547 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 2 | 2002 | 273 | 0.020 |
Why?
|
Blood Pressure | 3 | 2001 | 8525 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2000 | 2629 | 0.020 |
Why?
|
Graft Survival | 1 | 2001 | 3794 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 1999 | 4810 | 0.020 |
Why?
|
Postoperative Period | 1 | 1994 | 1818 | 0.020 |
Why?
|
Pleura | 1 | 1991 | 244 | 0.020 |
Why?
|
Cell Separation | 2 | 1987 | 1720 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 899 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1990 | 2094 | 0.020 |
Why?
|
Mice, Inbred BALB C | 3 | 2006 | 6216 | 0.020 |
Why?
|
HIV Infections | 1 | 2014 | 17165 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2004 | 15840 | 0.020 |
Why?
|
Diatrizoate | 1 | 1987 | 81 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12531 | 0.020 |
Why?
|
Ficoll | 1 | 1987 | 39 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 1990 | 1705 | 0.020 |
Why?
|
Heart Transplantation | 2 | 1998 | 3224 | 0.020 |
Why?
|
Cell Migration Inhibition | 1 | 2006 | 97 | 0.020 |
Why?
|
Lymphocytes | 2 | 2006 | 2611 | 0.020 |
Why?
|
Radiography, Thoracic | 2 | 2000 | 1296 | 0.020 |
Why?
|
Regression Analysis | 3 | 2004 | 6360 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 1991 | 1166 | 0.020 |
Why?
|
Chemokine CXCL9 | 1 | 2006 | 135 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1999 | 5125 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6538 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 12965 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2005 | 15789 | 0.020 |
Why?
|
Lung Diseases, Interstitial | 1 | 2014 | 911 | 0.020 |
Why?
|
Heart | 1 | 1998 | 4393 | 0.020 |
Why?
|
Receptors, CXCR3 | 1 | 2006 | 238 | 0.020 |
Why?
|
Blood Cells | 1 | 1987 | 305 | 0.020 |
Why?
|
Cohort Studies | 1 | 2008 | 41335 | 0.020 |
Why?
|
Chemokine CXCL10 | 1 | 2006 | 316 | 0.020 |
Why?
|
STAT1 Transcription Factor | 1 | 2006 | 333 | 0.020 |
Why?
|
High Mobility Group Proteins | 1 | 2005 | 176 | 0.020 |
Why?
|
Exercise | 2 | 1998 | 5787 | 0.010 |
Why?
|
Hemorrhage | 1 | 1996 | 3600 | 0.010 |
Why?
|
Body Mass Index | 1 | 2002 | 12914 | 0.010 |
Why?
|
Ventriculography, First-Pass | 1 | 2003 | 20 | 0.010 |
Why?
|
Critical Care | 1 | 1996 | 2699 | 0.010 |
Why?
|
SOXB1 Transcription Factors | 1 | 2005 | 286 | 0.010 |
Why?
|
Ovalbumin | 1 | 2005 | 674 | 0.010 |
Why?
|
Coronary Angiography | 1 | 1995 | 4563 | 0.010 |
Why?
|
Antigens, Surface | 1 | 1987 | 1608 | 0.010 |
Why?
|
Chronic Disease | 4 | 2000 | 9287 | 0.010 |
Why?
|
Respiration Disorders | 1 | 1986 | 368 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 3804 | 0.010 |
Why?
|
Biopsy | 2 | 2008 | 6771 | 0.010 |
Why?
|
Infant | 1 | 2024 | 36060 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1991 | 2536 | 0.010 |
Why?
|
Ventricular Pressure | 1 | 2002 | 204 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 1997 | 4925 | 0.010 |
Why?
|
Bronchiectasis | 1 | 2003 | 139 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2016 | 12427 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 1995 | 2543 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 1987 | 975 | 0.010 |
Why?
|
Polymorphism, Genetic | 2 | 2002 | 4291 | 0.010 |
Why?
|
Child, Preschool | 1 | 2024 | 42063 | 0.010 |
Why?
|
Administration, Sublingual | 1 | 2001 | 58 | 0.010 |
Why?
|
Diastole | 1 | 2003 | 788 | 0.010 |
Why?
|
Mice, Knockout | 2 | 2006 | 14372 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8624 | 0.010 |
Why?
|
United States | 2 | 2020 | 72461 | 0.010 |
Why?
|
Prognosis | 2 | 2004 | 29658 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 2000 | 169 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 1987 | 1765 | 0.010 |
Why?
|
Sulfones | 1 | 2002 | 447 | 0.010 |
Why?
|
Reference Values | 1 | 1987 | 4925 | 0.010 |
Why?
|
Bronchial Provocation Tests | 1 | 1999 | 216 | 0.010 |
Why?
|
Vasoconstriction | 1 | 2002 | 593 | 0.010 |
Why?
|
Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 29932 | 0.010 |
Why?
|
Reperfusion Injury | 1 | 2006 | 1023 | 0.010 |
Why?
|
Ligands | 1 | 2006 | 3276 | 0.010 |
Why?
|
Environmental Exposure | 2 | 1985 | 4412 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2016 | 58995 | 0.010 |
Why?
|
Purines | 1 | 2002 | 605 | 0.010 |
Why?
|
Child | 2 | 2024 | 79806 | 0.010 |
Why?
|
Pleural Effusion | 1 | 1982 | 342 | 0.010 |
Why?
|
Genetic Markers | 1 | 2005 | 2608 | 0.010 |
Why?
|
Gene Deletion | 1 | 2006 | 2668 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2006 | 3157 | 0.010 |
Why?
|
Bronchitis | 1 | 1998 | 196 | 0.010 |
Why?
|
Young Adult | 1 | 2024 | 58741 | 0.010 |
Why?
|
H-2 Antigens | 1 | 1978 | 358 | 0.010 |
Why?
|
Methylprednisolone | 1 | 1999 | 384 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2006 | 22023 | 0.010 |
Why?
|
Nitrogen | 1 | 1998 | 350 | 0.010 |
Why?
|
Heart Rate | 2 | 1999 | 4179 | 0.010 |
Why?
|
Up-Regulation | 1 | 2006 | 4122 | 0.010 |
Why?
|
Echocardiography | 2 | 2003 | 4981 | 0.010 |
Why?
|
Complement Activation | 1 | 1999 | 446 | 0.010 |
Why?
|
Acidosis, Lactic | 1 | 1998 | 145 | 0.010 |
Why?
|
Collagen | 1 | 2005 | 2636 | 0.010 |
Why?
|
Models, Chemical | 1 | 1999 | 614 | 0.010 |
Why?
|
Body Surface Area | 1 | 1997 | 197 | 0.010 |
Why?
|
Heart-Lung Transplantation | 1 | 1997 | 87 | 0.010 |
Why?
|
Isoantigens | 1 | 1979 | 552 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2006 | 18137 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1982 | 1557 | 0.010 |
Why?
|
Lactates | 1 | 1997 | 404 | 0.010 |
Why?
|
Airway Obstruction | 1 | 2001 | 662 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2001 | 2234 | 0.010 |
Why?
|
Phosphorus | 1 | 1997 | 333 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 36290 | 0.010 |
Why?
|
Family Health | 1 | 2000 | 1257 | 0.010 |
Why?
|
Animals | 6 | 2006 | 167963 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 3 | 2002 | 17790 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 1995 | 6659 | 0.010 |
Why?
|
Macrophages | 1 | 1990 | 5745 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2000 | 857 | 0.010 |
Why?
|
Thrombophlebitis | 1 | 1995 | 288 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 1998 | 1146 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12446 | 0.010 |
Why?
|
Isoantibodies | 1 | 1978 | 661 | 0.010 |
Why?
|
Rats | 1 | 1990 | 23711 | 0.010 |
Why?
|
ROC Curve | 1 | 2001 | 3568 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2001 | 14660 | 0.010 |
Why?
|
Risk | 1 | 1985 | 9631 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2005 | 9530 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2001 | 22053 | 0.010 |
Why?
|
Asthma | 1 | 1991 | 6172 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 6498 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1997 | 2502 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1979 | 1998 | 0.010 |
Why?
|
Mice | 4 | 2006 | 81208 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2003 | 3880 | 0.010 |
Why?
|
Neutrophils | 1 | 1982 | 3767 | 0.010 |
Why?
|
Family | 1 | 1999 | 3189 | 0.000 |
Why?
|
Vascular Diseases | 1 | 1997 | 1182 | 0.000 |
Why?
|
Lymphedema | 1 | 1995 | 524 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 9585 | 0.000 |
Why?
|
Neoplasm Staging | 1 | 1983 | 11152 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1997 | 3765 | 0.000 |
Why?
|
Homeostasis | 1 | 1997 | 3306 | 0.000 |
Why?
|
Prospective Studies | 2 | 2001 | 54303 | 0.000 |
Why?
|
Epitopes | 2 | 1979 | 2503 | 0.000 |
Why?
|
Electrocardiography | 1 | 1995 | 6414 | 0.000 |
Why?
|
Multiple Myeloma | 1 | 1978 | 5130 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 1997 | 20080 | 0.000 |
Why?
|
Ascitic Fluid | 1 | 1979 | 189 | 0.000 |
Why?
|
Plasmacytoma | 1 | 1979 | 171 | 0.000 |
Why?
|
Mice, Inbred DBA | 1 | 1979 | 622 | 0.000 |
Why?
|
Prevalence | 1 | 1995 | 15687 | 0.000 |
Why?
|
Antigen-Antibody Reactions | 1 | 1978 | 346 | 0.000 |
Why?
|
Cross Reactions | 1 | 1979 | 818 | 0.000 |
Why?
|
Incidence | 1 | 1995 | 21392 | 0.000 |
Why?
|
Neoplasm Transplantation | 1 | 1978 | 2014 | 0.000 |
Why?
|
Neoplasms, Experimental | 1 | 1978 | 1229 | 0.000 |
Why?
|
Immune Tolerance | 1 | 1979 | 2299 | 0.000 |
Why?
|